Sterling Investment Advisors Ltd. Grows Position in Pfizer Inc. $PFE

Sterling Investment Advisors Ltd. raised its holdings in Pfizer Inc. (NYSE:PFE) by 14.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 143,333 shares of the biopharmaceutical company’s stock after buying an additional 18,581 shares during the period. Sterling Investment Advisors Ltd.’s holdings in Pfizer were worth $3,451,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. California State Teachers Retirement System lifted its holdings in shares of Pfizer by 2,320.6% in the 2nd quarter. California State Teachers Retirement System now owns 217,981,455 shares of the biopharmaceutical company’s stock worth $5,248,993,000 after buying an additional 208,976,273 shares during the period. Norges Bank purchased a new stake in Pfizer in the fourth quarter worth about $1,830,986,000. Bank of America Corp DE bought a new position in Pfizer during the 2nd quarter worth about $1,049,602,000. BlackRock Inc. increased its position in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. Finally, Morgan Stanley raised its holdings in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s recent quarterly results exceeded expectations, with adjusted earnings per share of $0.77 versus a $0.68 consensus estimate and revenue of $15.03 billion, above the $14.40 billion forecast. The earnings beat helped revive the shares during August and supports confidence in the company’s ability to execute despite post-COVID revenue challenges. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Pfizer’s roughly 6% dividend yield remains a major attraction for income-focused investors. Some analysts also see upside from a pipeline that is beginning to gain investor attention, with one commentary assigning a 12-month price target of $32.72 based on dividend support and potential pipeline progress. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
• Neutral Sentiment: Chief Executive Officer Albert Bourla is scheduled to speak at the Morgan Stanley Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, capital allocation and the company’s growth strategy. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Negative Sentiment: Pfizer’s high yield is not viewed as the strongest dividend-growth opportunity. Comparisons with AbbVie argue that Pfizer offers income today but may have less attractive long-term dividend growth, potentially limiting demand from total-return investors. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
• Negative Sentiment: Novartis India’s $132 million acquisition of Pfizer brands indicates continued portfolio reshaping, but the divestiture also removes established products and revenue from Pfizer’s business. Meanwhile, Lilly’s expanding neuroscience pipeline highlights intensifying competition for future growth in innovative medicines. Novartis India Acquires Pfizer Brands

Pfizer Trading Down 2.4%

PFE opened at $27.78 on Wednesday. The company’s 50 day simple moving average is $26.13 and its two-hundred day simple moving average is $26.35. The firm has a market capitalization of $158.34 billion, a price-to-earnings ratio of 36.55, a price-to-earnings-growth ratio of 1.91 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $29.21.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Ratings Changes

Several research firms have commented on PFE. UBS Group reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. JPMorgan Chase & Co. cut their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.28.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.